Showing results (101-110 of 204) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesOwen A O'Connor, Steven Horwitz, Paul Hamlin, et al.
Genes, Chromosomes & Cancer|August 29, 2025
Comparative DNA Methylation Profiling of Human and Murine ALK-Positive B-Cell NeoplasmsSelina Glaser, Rabea Wagener, Shannon K Harkins, et al.
British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
British Journal of Haematology|March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomasJacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2010
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa regionAli Bazarbachi, Hamdy A Azim, Hussain Alizadeh, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
The Journal of Experimental Medicine|August 24, 2011
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphomaJonathan H Schatz, Elisa Oricchio, Andrew L Wolfe, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Blood|January 12, 2012
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseAnn S LaCasce, Jonathan L Vandergrift, Maria A Rodriguez, et al.
Pageof 21